Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Emerging clinical literature has stirred interest in their relevance to many PMOS-related symptoms
Cosentyx (secukinumab) Disease area(s): Immunology Manufacturer(s): Novartis 2024 Sales (USD): $6.14 billion Why it sold so well: In 2024, Novartis Cosentyx registered significant sales growth, with revenues increasing by 23% year-over-year to $6.14 billion
Depression: The case for a monoamine deficiency
We are dedicated to providing compassionate care that respects every individuals unique journey, combining advanced medical science with modern technology
Studies suggest that tirzepatide-based medication may lead to greater weight loss than semaglutide-based medication
Thompson A, Kanamarlapudi V
US$ 26.77
US$ 27.33
US$ 28.36
US$ 22.46
US$ 21.89
US$ 21.06
US$ 28.89
US$ 26.26
US$ 22.53
US$ 29.21
